Sepracor study compares Lunesta effectiveness among ethnic groups

By Elaine Rigoli

Tampa, Fla., June 21 - Sepracor, Inc. said a double-blind, placebo-controlled six-month trial comparing race/ethnicity with Lunesta brand eszopiclone for the treatment of insomnia showed that in 1,581 patients, Caucasians (1,195) and African-Americans (236) administered Lunesta achieved statistically significant improvements across each measurement of sleep and next-day function over the treatment period versus those patients administered a placebo.

However, among Hispanic patients (150), improvements across all sleep and next-day function parameters were not statistically significant.

The company said this could be due to the small number of patients in this cohort.

The company also announced post-hoc analysis based on a separate eight-week randomized double-blind placebo-controlled 545-patient study of Lunesta in combination with fluoxetine in the treatment of patients with insomnia and co-existing major depressive disorder.

This analysis showed that patients in the Lunesta-fluoxetine treatment group demonstrated statistically significant improvements versus the placebo-fluoxetine treatment group at weeks four and eight.

Sepracor is a research-based pharmaceutical company with corporate headquarters in Marlborough, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.